Immunovant, Inc.
IMVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001764013
In the last 90 days, Immunovant, Inc. insiders filed 0 open-market purchases and 10 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.25B in total; Greenlight Capital is the only superinvestor holding it.
13F holders, Q3 2022
Institutional positions in Immunovant, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 112
- +18 vs. Q2 2022
- Shares held
- 42.7M
- +2.53M (+6.3%) vs. Q2 2022
- Total value
- $238.1M
- +$81.6M (+52.1%) vs. Q2 2022
- New holders
- 23
- 36 more added
- Sold out
- 5
- 33 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IMVT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 226 | $4.25B |
| Q1 2026 | 216 | $2.75B |
| Q4 2025 | 197 | $2.76B |
| Q3 2025 | 186 | $1.53B |
| Q2 2025 | 169 | $1.54B |
| Q1 2025 | 194 | $1.62B |
| Q4 2024 | 187 | $1.98B |
| Q3 2024 | 182 | $2.26B |
| Q2 2024 | 197 | $1.97B |
| Q1 2024 | 209 | $2.27B |
| Q4 2023 | 228 | $2.88B |
| Q3 2023 | 181 | $2.57B |
| Q2 2023 | 147 | $1.05B |
| Q1 2023 | 142 | $903.7M |
| Q4 2022 | 133 | $1.00B |
| Q3 2022 | 112 | $238.1M |
| Q2 2022 | 94 | $156.5M |
| Q1 2022 | 112 | $218.6M |
| Q4 2021 | 118 | $322.4M |
| Q3 2021 | 119 | $293.6M |
| Q2 2021 | 110 | $407.5M |
| Q1 2021 | 120 | $654.3M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Immunovant, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 811,700 | $4.53M | 2.26% | +811,700 | New |
| Geode Capital Management, LLC | 813,669 | $4.54M | 0.00% | +18,697+2.4% | Added |
| State Street Corp | 878,601 | $4.90M | 0.00% | −14,079−1.6% | Reduced |
| Dimensional Fund Advisors LP | 1,058,459 | $5.91M | 0.00% | +112,979+11.9% | Added |
| Woodline Partners LP | 1,764,290 | $9.85M | 0.14% | +1,672,190+1,815.6% | Added |
| Point72 Asset Management, L.P. | 1,967,300 | $11.0M | 0.05% | +1,967,300 | New |
| BlackRock Inc. | 3,506,674 | $19.6M | 0.00% | −124,636−3.4% | Reduced |
| Vanguard Group Inc | 4,000,450 | $22.3M | 0.00% | +9570.0% | Added |
| Alpine Global Management, LLC | 4,348,017 | $24.3M | 5.68% | −100,000−2.2% | Reduced |
| Eventide Asset Management, LLC | 5,372,512 | $30.0M | 0.59% | 00.0% | Unchanged |
| Deep Track Capital, LP | 9,860,246 | $55.0M | 2.72% | +405,246+4.3% | Added |
| IFP Advisors, Inc | 10 | – | – | 00.0% | Unchanged |
| DuPont Capital Management Corp | 0 | $0 | 0.00% | −34,088−100.0% | Sold out |
| Bridgefront Capital, LLC | 0 | $0 | 0.00% | −15,649−100.0% | Sold out |
| Penserra Capital Management LLC | 0 | $0 | 0.00% | −3,597−100.0% | Sold out |
| International Biotechnology Trust PLC | 0 | $0 | 0.00% | −233−100.0% | Sold out |
| PEAK6 Investments LLC | 0 | $0 | 0.00% | −13,000−100.0% | Sold out |